Tag Archives: MAT

Water-Based Vaping Breakthrough Unveiled At UKVIA Forum

Water-based vaping technology developed by Aquios Labs and Innokin continues to impress the vaping industry

LONDON, Nov. 19, 2022 /PRNewswire/ — The Vaping Industry Forum and Awards Dinner, organised by the UK Vaping Industry Association (UKVIA), is a significant date in the vaping industry’s calendar. On Friday 18th November 2022, some 300 delegates, including policymakers, tobacco harm reduction experts and representatives from vaping industry met to discuss the event’s theme, “Vaping for a Better Future”.

The vaping industry seeks to disrupt the combustible tobacco industry with less harmful products. Leading brands are developing new technologies to make next generation nicotine a more effective platform for adult smokers.

Vaping industry veterans Innokin have a long history of Innovation. Recent awards include “Best Overall Vape Brand” at the Ecigclick Awards 2021, “best sustainable initiative” at the Vapouround Awards 2022, and “Biggest Breakthrough Innovation” at the Golden Leaf Awards 2022, the latter of which were earned for the introduction of water-based vaping technology, developed in partnership with Aquios Labs.

Innokin says water-based vaping was developed to deliver smoother vapour, faster satisfaction and more accurate flavours, while enhancing the potential for harm reduction. These benefits are achieved using a proprietary e-liquid formulation with 30% water content and new vaping hardware tailored to thinner liquids. Independent testing by TCT Lab has demonstrated that water-based vaping reduces acetaldehyde and formaldehyde emissions by 91% and 81% respectively compared to traditional vapes.

Now, Innokin and Aquios Labs have added another water-based vape to their portfolio with the INNOBAR C1, unveiled to harm reduction and industry experts at the UKVIA Forum.

The INNOBAR C1 is the world’s first pre-filled pod system to take advantage of water-based vaping technology. Innokin says this allows the device to “deliver next-generation performance, at a more affordable price and with less waste compared to disposable vaping devices”. Unlike disposable devices, The INNOBAR C1 uses a rechargeable battery, combined with pre-filled “pods” to allow for enhanced performance and greatly reduced waste.

Water-based vaping technology is now set to gain momentum in the global vaping industry, as major brands and harm reduction experts seek to find new ways to improve the efficacy of vaping products.

Speaking at the UKVIA Forum “Innovating in the vaping sector” panel, Innokin UK Branding Manager, Benedict Jones said: “The process of listening to customers and trying to understand their challenges is central to our product strategy. Our goal is always to reduce the number of barriers between a transitioning smoker and a less harmful alternative.

Innokin UK Branding Manager, Benedict Jones
Innokin UK Branding Manager, Benedict Jones

By integrating water-based vaping technology, INNOBAR C1 delivers smoother vapour, greater nicotine satisfaction and reduced dehydration, at a lower vaping temperature with improved chemical stability. We are excited to continue development of this technology with our partner Aquios Labs.”

Innokin and Aquios Labs have already launched several disposable vaping devices with water-based vaping technology, alongside their latest pre-filled pod device, the INNOBAR C1. Innokin are now developing refillable vaping devices which can make use of water-based e-liquids, such as pods and tanks. 

In the run up to the Ecigclick Awards 2022 and the next Vaper Expo UK in May 2023, Innokin and Aquios Labs plan to expand their unique water-based vaping portfolio to reach all segments of the growing vaping market.

For more information:

https://innokin.com?utm_source=PR+newswire&utm_medium=press+release&utm_campaign=UKVIA

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/water-based-vaping-breakthrough-unveiled-at-ukvia-forum-301683273.html

The Johns Hopkins University’s Institute for Global Tobacco Control updates its free online course on the dangers of tobacco use and COVID-19

BALTIMORE, Feb. 18, 2022 — With the COVID-19 pandemic still a concern as 2022 begins, arm yourself with knowledge about the connection between tobacco use and COVID-19 with a free online course from the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health.

Arm yourself with knowledge about the connection between tobacco use and COVID-19 with a free online course from the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health.
Arm yourself with knowledge about the connection between tobacco use and COVID-19 with a free online course from the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health.

Updated with new information in late 2021, COVID-19 and Tobacco Use covers topics such as the impact of smoking on COVID-19, the effects of nicotine at a molecular level, and the behavior of the tobacco industry during the pandemic.

Current evidence shows the negative impacts of smoking on COVID-19 outcomes, providing one more compelling reason and an added sense of urgency for people to quit using tobacco products. As infections continue to disrupt daily living, any step taken to curb the negative outcomes of COVID-19 should be explored and implemented. This course can help amplify that effort.

The COVID-19 and Tobacco Use course joins a distinguished suite of existing free online courses, which have been completed by more than 6,700 participants from more than 100 countries around the world.

Global Tobacco Control: Learning from the Experts is a comprehensive primer on the tobacco epidemic featuring 27 subject matter experts from 14 countries. Participants in the course will get a unique global perspective on the burden of tobacco on death and disease and evidence-based solutions to reduce it.

Learning from the Experts: A Course for Healthcare Providers is an online course developed with input from globally acclaimed tobacco control advocates in healthcare careers. Designed for busy healthcare providers, this course provides up-to-date information about the role healthcare professionals can play in tobacco control, and how to help their patients quit tobacco. Recent updates to the course include how cessation medication works; how to help a patient quit smokeless tobacco and other non-cigarette tobacco products; and addressing practical issues clinicians face when helping their patients quit tobacco.

All three courses are free to any user around the world and feature a responsive design that allows users to take the course at their own pace on any device. Users who complete a course receive a certificate of completion from the Institute for Global Tobacco Control.

ICCPP Ushers “Powder-free” Atomization Technology with Next-Generation GENE TREE Ceramic Cores

SHENZHEN, China, Sept. 18, 2021 — ICCPP, a global atomization company, has unveiled its first-ever ceramic core technology brand GENE TREE at the 2021 Nano-tech Ceramic Core Global Online Launch Conference on September 16. The release of GENE TREE marks a revolution in electric atomization R&D while also introducing a new generation of ceramic core products into the industry.

2021 Nano-tech Ceramic Core Global Online Launch Conference
2021 Nano-tech Ceramic Core Global Online Launch Conference

Themed "The Future of the Core", the conference emphasized the continued development and innovations of electronic atomization technology, as well as demonstrating ICCPP’s determination to shape the future of the industry. Its new GENE TREE nano-tech ceramic core products promise to improve the efficiency and stability of atomization and increase product lifespan.

"GENE TREE is the culmination of countless hours of R&D and almost a decade of experience in electric atomization technology. We are thrilled to launch our breakthrough research achievement with the international community and usher in the future of ceramic cores," said ICCPP CEO EVEREST Zhao.

ICCPP has established a 300-strong R&D team. GENE TREE nano-tech ceramic core products were realized by this team after over 1,000 days spent on repeating technical explorations and scientific experiments and tens of thousands of hours spent refining one thousand sets of ceramic core material formulations. In addition, the R&D team overcame a series of technical production challenges to ensure mass-produced ceramic cores were at a world-class level in terms of resistance consistency and appearance.

GENE TREE Ceramic Cores
GENE TREE Ceramic Cores

With the "powder-free" concept, GENE TREE products harness raw materials made from new environmentally-friendly mineral materials, which migrate and diffuse into the three-dimensional network ceramic skeleton at a high temperature. Following this, the grain micro-structure is rebuilt and the multi-phase co-existence structure improves the ceramic toughness. Meanwhile, dispersion is distributed in the three-dimensional ceramic skeleton to form a lipophilic matrix layer, which can improve the lipophilicity and oil storage of porous ceramic. Atomization tests have demonstrated that the temperature of the ceramic heating surface and atomization remains stable between four to 11 watts.

Unlike other products, GENE TREE’s safe operation power range can also be raised from 8 watts to 11 watts to fully meet the requirements of different products. The heating film remains stable in temperature and the GENE TREE supports continuous atomization for 4000 seconds — increasing its lifespan by five times compared with other mainstream products.

As ICCPP’s first ceramic core product, GENE TREE has garnered widespread attention from the industry since its launch. With plans to ramp up production capacity and sales for B2B clients, GENE TREE has established itself as a key player straight out of the gate, as well as the leader in electric atomization technology.

About ICCPP

ICCPP is a global technology group with nearly a decade of experience in technology research and development, product design, manufacturing, brand building and other fields. Its products and services are distributed in more than 70 countries and regions, with approximately 30 million users.

Tingkai Xu
kai@voopootech.com
+86-15957944779

Cambridge Isotope Laboratories, Inc. is Now Offering Cannabis Standards for MS-based Testing


TEWKSBURY, Mass., Aug. 31, 2021 — CIL now offers solutions for testing the quality and safety of Cannabis products with the launch of a variety of stable-isotope labeled and native standards of THC, CBD, and other cannabinoids to assist with testing needs.

Research suggests the cannabis plant produces between 80-100 cannabinoids, primarily cannabidiol (CBD) and tetrahydrocannabinol (THC). The complexity and diversity of cannabis products poses unique challenges to accurate quality testing and Cannabis testing laboratories must meet the needs of varying state and federal requirements to ensure products are safe, effective, and consistent.

Ben Priest, Business Development Manager for Environmental Products at CIL, states "The increased use of mass spectrometry in cannabis testing has enabled testing facilities to offer a greater degree of accuracy and precision. CIL’s high purity analytical reference standards facilitate accurate strain identification, potency testing, and adulterant analysis." 

"The cannabis reference standards provide an accurate analytical means to measure and quantify the presence and concentration of targets in a wide range of samples, including plant material, pharmaceuticals, personal care products, food, and beverages, says CIL’s Senior Applications Chemist, Mass Spectrometry, Andrew Percy, Ph.D. "Due to their high characterization, users can be assured that the CIL standards implemented for method development and application will lead to robust and accurate results that can be trusted in safety, quality, stability, and consistency testing."

To learn more about CIL’s Cannabis testing standards including cannabinoids and other common pesticides related to cannabis testing, visit isotope.com.

About Cambridge Isotope Laboratories, Inc.   

CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France.   

For more information on CIL, visit isotope.com.

Contact Information:
Crissy Krisko
Phone: 1.978.749.8000 
Fax: 1.978.749.2768 
www.isotope.com

Related Images

cambridge-isotope-laboratories-inc.jpg
Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories, Inc.